Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases

Autor: Marta del Álamo, Christoph Bührer, Dirk Fisher, Matthias Griese, Paul Lingor, Giovanni Palladini, Nicolas Sireau, Virginie Hivert, Luca Sangiorgi, Florence Guillot, Juliane Halftermeyer, Lenka Soucková, Kristýna Nosková, Regina Demlová

Publikováno v: Trials, Vol 23, Iss 1, Pp 1-10 (2022)

Abstract Background Academic-sponsored trials for rare diseases face many challenges; the present paper identifies hurdles in the set-up of six multinational clinical trials for drug repurposing, as use cases. Methods Six academic-sponsored multinati

Externí odkaz: https://doaj.org/article/aa7ef21410884d95a66ff184ad0ef663

Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases.

Autor: del Álamo, Marta¹ (AUTHOR) marta.delalamo@ecrin.org, Bührer, Christoph² (AUTHOR), Fisher, Dirk³ (AUTHOR), Griese, Matthias⁴ (AUTHOR), Lingor, Paul⁵ (AUTHOR), Palladini, Giovanni⁶ (AUTHOR), Sireau, Nicolas⁷ (AUTHOR), Hivert, Virginie⁸ (AUTHOR), Sangiorgi, Luca⁹ (AUTHOR), Guillot, Florence¹⁰ (AUTHOR), Halftermeyer, Juliane¹¹ (AUTHOR), Soucková, Lenka^1,12 (AUTHOR), Nosková, Kristýna^1,12 (AUTHOR), Demlová, Regina¹² (AUTHOR)

Publikováno v: Trials. 9/15/2022, Vol. 23 Issue 1, p1-10. 10p. 3 Charts.

Už máte svého terapeuta nebo kouče?

Publikováno v: Psychologie Dnes. 2021, Issue 12, p29-29. 1p.

Už máte svého terapeuta nebo kouče?

Publikováno v: Psychologie Dnes. 2021, Issue 7/8, p51-51. 1p.

Sunitinib: Mechanisms, Interactions and Side Effects

Autor: Vasso Anastasia

Tyrosine kinase inhibitors are used to treat patients with advanced thyroid cancers. Sunitinib (SU11248) is an oral small-molecule, oxindol derivative, multi-targeted tyrosine kinase inhibitor that inhibits receptors for platelet-derived growth facto